Safety concerns trump efficacy in Phase III trials of Affymax/Takeda's anaemia drug
This article was originally published in Scrip
Executive Summary
Top-line data from four Phase III trials of Affymax/Takeda's Hematide (peginesatide), for the treatment of anaemia in chronic renal failure, show that the drug met all its primary endpoints, but cardiovascular safety concerns spooked investors.